Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

CAR-T Treatment Costs Beyond Therapy Acquisition Costs in Multiple Myeloma Patients

Speaker(s)

Jagannath S1, Joseph N2, Crivera C3, Jackson CC4, Valluri S5, Cost P5, Phelps H5, Slowik R5, Klein TM6, Smolen L6, Yu X6, Cohen A7
1Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2Janssen Scientific Affairs, LLC, Phoenixville, PA, USA, 3Janssen Scientific Affairs, LLC, Horsham, PA, USA, 4Janssen R&D, Raritan, NJ, USA, 5Janssen Global Services, LLC, Raritan, NJ, USA, 6Medical Decision Modeling Inc., Indianapolis, IN, USA, 7University of Pennsylvania, Philadelphia, PA, USA

Presentation Documents

OBJECTIVES: Chimeric antigen receptor T (CAR-T) cell therapies are newly developed treatments for relapsed refractory multiple myeloma (RRMM) patients who have been triple-class exposed (i.e., proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies during treatment). CAR-T acquisition costs are known and readily available, however other costs associated with CAR-T therapy, such as the required pre-, peri-, and post-infusion costs are unknown. This study estimated healthcare costs related to CAR-T therapy (i.e., costs separate from CAR-T therapy acquisition) for RRMM patients.

METHODS: Clinical trial data and published literature were used to identify the components (and costs) of pre-, peri-, and post-infusion processes associated with CAR-T. Pre-infusion costs included evaluation, apheresis, bridging therapy, and conditioning therapy costs. Inpatient or outpatient infusion costs, separate from CAR-T therapy acquisition costs, were included in peri-infusion costs. One-hundred-day post-infusion monitoring costs, other infusion monitoring costs required in the first year, and costs associated with managing serious adverse event (AE) associated with the CAR-T therapy were quantified as post-infusion costs. AEs that required prolonged hospitalization or resulted in death were classified as serious AEs.

RESULTS: The estimated costs of the pre- and peri-infusion components of CAR-T therapy for RRMM patients, excluding CAR-T therapy acquisition costs, totaled $22,865. The most expensive component of the combined pre- and peri-infusion costs was bridging therapy ($16,370) followed by inpatient infusion ($3,215), conditioning therapy ($3,168), and apheresis ($112). Post-infusion costs were found to vary among CAR-T therapies.

CONCLUSIONS: This study quantified the overall estimated healthcare costs associated with the use of CAR-T treatment among triple-class exposed RRMM patients. Results from the analysis provide valuable, holistic information required by healthcare decision-makers to make informed choices.

Code

EE70

Topic

Economic Evaluation

Disease

Genetic, Regenerative and Curative Therapies